

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/25483

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.1, 6; 424/138.1; 514/2, 44; 536/23.5, 23.2; 530/300, 350, 387.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, BIOSIS, CAPLUS, EMBASE, GENBANK
search terms: p27kip1, ?kip1, p27, cyclin, prostate

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X - Y	US 5,688,665 A (MASSAGUE et al.) 18 November 1997, figure 7c; figure 12; column 52, lines 12-13; abstract. column 3, lines 59-65 and column 4, lines 14-26.	3,4,6,7,9-13 ----- 5,8
X	HENGST, et al. Translational control of p27Kip1 accumulation during the cell cycle. Science. 29 March 1996, Vol. 271, pages 1861-1864, especially page 1861 and figures 1 and 2.	1-4, 11-13

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
18 FEBRUARY 1999Date of mailing of the international search report
02 MAR 1999Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230Authorized officer:
NANCY A. JOHNSON
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/25483

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X - Y	POLYAK, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 15 July 1994, Vol. 78, pages 59-66, especially pages 59 and 60, especially page 62.	1,4 ---- 6,7
X	PONCE-CASTANEDA, et al. p27Kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Research. 15 March 1995, Vol. 55, pages 1211-1214, especially page 1213.	6
X,P ---- Y,P	KOKONTIS, et al. Progression of LNCaP prostate tumor cells during androgen deprivation: Hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Molecular Endocrinology. 1998, Vol. 12, pages 941-853, especially page 950 and figure 8, especially page 945.	2,11,12 ----- 10,13
X,P	GUO et al. Loss of the cyclin-dependent kinase inhibitor p27Kip1 protein in human prostate cancer correlates with tumor grade. Clinical Cancer Research. December 1997, Vol 3, pages 2269-2274, especially pages 2270 and 2271.	1,4,12,13
X,P	COTE et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. Journal of the National Cancer Institute. 17 June 1998, Vol. 90, No. 12, pages 916-920, especially pages 917 and 918.	1,4,12
A	KNUDSEN, et al. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. Journal of Biological Chemistry. 07 August 1998, Vol. 273, No. 32, pages 20213-20222.	1-13
A	POLYAK, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes & Development. 1994, Vol. 8, pages 9-22.	1-13
A	CAMPBELL, et al. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. Journal of Molecular Endocrinology. 1997, Vol. 19, pages 15-27.	10, 13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/25483

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

G01N 33/53, 33/68; C12Q 1/168; A61K 31/00, 39/395, 38/02, 48/00; C07H 21/04; C07K 14/47, 16/18, 16/40

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

435/7.1, 6; 424/138.1; 514/2, 44; 536/23.5, 23.2; 530/300, 350, 387.7